Season 1 of Raising Biotech dives into the global playing field of biotech startups, revealing how geography can make or break a company’s early-stage success. Whether you're in a biotech powerhouse like Boston or halfway around the world in Australia, the journey to securing capital and scaling operations looks drastically different. The stories of founders featured this season show just how much location influences a startup’s trajectory and the lengths some entrepreneurs go to in order to gain traction.
The Power of US Biotech Hubs
For those in the US, especially in the nation’s biotech hotspots, the road to funding looks quite different. Empress Therapeutics and Alltrna, both backed by Flagship Pioneering, have access to an unmatched ecosystem. Being plugged into Boston’s biotech scene or Silicon Valley’s venture networks means access to a deep pool of capital and expertise tailored to high-risk, high-reward biotech ventures. With venture capitalists who understand the intricacies of scaling complex scientific platforms, these companies can secure major rounds of funding faster than their international counterparts, putting them miles ahead before the race even begins.
Michelle Werner of Alltrna pointed out how pivotal Flagship’s support was in fast-tracking their platform development, highlighting that being in the US biotech circuit provides not only financial backing but also strategic expertise that’s hard to find elsewhere. It’s a luxury not every founder can access, especially those outside US borders.
The ex-US Challenge: Finding Traction in Unfamiliar Territory
For founders outside the US, the journey often starts with a steep uphill battle. Tom Oxley of Synchron, for instance, initially tried to raise capital in Australia. Despite having groundbreaking technology in brain-computer interfaces, he faced a market not ready to embrace the risks associated with such innovation. Realizing the limits of the local investment landscape, Oxley moved operations to the US, which was the decision that changed the game. Almost instantly, he secured the funding he needed, proving that sometimes, relocating is the price of progress. “The difference was night and day,” he explained; the US was simply more willing to bet on the future of neurotechnology.
Jack O’Meara of Ochre Bio had a similar story but played it out in Europe. Despite a strong research foundation in Oxford, the investor pool was small and risk-averse, making it difficult to secure the capital needed to advance their innovative liver platform. So, O’Meara packed his bags and spent six months in Silicon Valley, plugging into the energy and resources of the US biotech scene. The gamble paid off, and Ochre Bio quickly locked down its Series A. It’s a testament to the fact that sometimes, success isn’t just about what you know -- it’s about where you are.
Tapping into Global Markets: Beyond the US Border
But it’s not just about the US advantage as some companies are taking a global view from the start. eGenesis, for instance, isn’t stopping with US trials. With its work on genetically modified pig organs for transplantation, eGenesis is looking beyond American shores, expanding trials to Japan, where organ shortage is much greater vs the west. Mike Curtis highlighted how crucial it is to think globally and adapt strategies to align with markets that might be more receptive to innovation. It’s a calculated move -- one that could accelerate their global launch and set them apart as leaders in xenotransplantation.
Other companies, like Arialys Therapeutics, are playing the long game. While their early funding from strategic US-based venture capitalists has set them up for success in the US market, CEO Jay Lichter knows that global expansion may demand further partnerships. Building an international presence and reaching a global population could mean joining forces with larger pharmaceutical firms that have the resources and infrastructure to bring their therapies to the masses. It’s a pragmatic approach -- one that recognizes the limits of being a small player in a global field.
The Bottom Line
Season 1 of Raising Biotech shows that where a company is based can make all the difference. For US founders, the path is often paved with easier access to capital and strategic resources. But for those outside the US, success frequently requires bold moves -- whether that’s relocating to a new country or strategically expanding clinical trials across the globe. At the end of the day, innovation knows no borders, but getting the backing to bring that innovation to life? Sometimes, it’s all about location.
Curious to hear more about how these biotech startups are navigating international growth and investment? Tune into Season 1 of Raising Biotech for exclusive insights from founders who are breaking down barriers and building global biotech empires.